Teva launches generic opioid addiction treatment

NORTH WALES, Pa. — Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII. 

 

This product is AB rated and is the generic equivalent of Reckitt Benckiser's Suboxone, which is indicated to treat adults who are addicted to opioid drugs. 

 

“Our customers count on Teva for a continuous supply of new generic products,” said Maureen Cavanaugh, SVP U.S. generics sales and marketing. “With the launch of Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”